We are live on ! Find out more
RGLS

Regulus Therapeutics

Delisted

RGLS was delisted on the 24th of June, 2025.

103 hedge funds and large institutions have $299M invested in Regulus Therapeutics in 2015 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,559% more call options, than puts

Call options by funds: $12.7M | Put options by funds: $768K

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

32% more capital invested

Capital invested by funds: $226M → $299M (+$72.7M)

17% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 29

12% more funds holding

Funds holding: 92103 (+11)

Holders
103
Holders Change
+11
Holders Change %
+11.96%
% of All Funds
2.7%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
20
Increased
34
Reduced
29
Closed
8
Calls
$12.7M
Puts
$768K
Net Calls
+$12M
Net Calls Change
+$4.59M

RGLS Hedge Fund Activity: Q4 2015 in Review

103 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2015, worth a combined $299M — up 32% from $226M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RGLS positions and 8 closed out — a net gain of 12 holders — while 34 added to existing stakes and 29 trimmed.

The largest buyer was UBS AM, adding an estimated $3.74M. The largest seller was Cormorant Asset Management, cutting an estimated $7.23M.

  • 103 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2015, up from 92 in Q3 2015.
  • Funds reported $299M of Regulus Therapeutics stock for Q4 2015, up 32% quarter-over-quarter.
  • 20 funds opened new Regulus Therapeutics positions in Q4 2015 and 8 closed out, a net change of +12 holders.
  • The largest Regulus Therapeutics buyer in Q4 2015 was UBS AM, an estimated $3.74M added.
  • The largest Regulus Therapeutics seller in Q4 2015 was Cormorant Asset Management, an estimated $7.23M sold.

Based on aggregated 13F filings for Q4 2015.